Abstract
This chapter provides an update on COVID-19 vaccines, emphasizing their immunogenicity, safety, efficacy, and potential impact on vaccine hesitancy, inequity, and future epidemic preparedness. Various vaccine types, such as mRNA-based, DNA-based, viral vector, inactivated, and protein subunit vaccines, are explored, evaluating their mechanisms and advantages in eliciting robust immune responses. Safety is thoroughly assessed using clinical trials and real-world data to address hesitancy concerns. Strategies for equitable distribution are discussed to achieve widespread coverage and overcome barriers. Lessons drawn from the pandemic serve as a roadmap for proactive measures aimed at bolstering epidemic preparedness, highlighting the critical role of global cooperation and equitable vaccine distribution in safeguarding public health worldwide.
Reference101 articles.
1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews. Microbiology. 2021;(3):141-154. DOI: 10.1038/s41579-020-00459-7
2. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. 2023. Available from:
3. World Economic Forum (WEF). World Vs Virus Podcast: An Economist Explains What COVID-19 has done to the Global Economy. 2020. Available from:
4. United Nations (UN). WHO Continues to Urge China to Share More Data Amid COVID-19 Surge. 2023. Available from:
5. Morens DM, Fauci AS. Emerging pandemic diseases: How we got to COVID-19. Cell. 2020;(3):837. DOI: 10.1016/j.cell.2020.10.022